Palliative treatment of painful bone metastases with MR imaging-guided focused ultrasound surgery: a two-centre study

Fulvio Zaccagna1*, Brachetti Giulia1, Alberto Bazzocchi2, Paolo Spinnato1, Ugo Albisinni1, Alessandro Napoli1, Carlo Catalano1


Background/introduction
To evaluate the efficacy of non-invasive high intensity MR guided focused Ultrasound Surgery (MRgFUS) for pain palliation of bone metastasis in patients who had exhausted EBRT or refused other therapeutic options.

Methods
This is a prospective, single arm, multicentre study performed after IRB approval. 72 patients (female: 24, male: 48, mean age: 61.6) with painful bone metastases were enrolled. 87 non-spinal lesions underwent MRgFUS treatment using ExAblate 2100 system (InSightec). European Organization for Research and Treatment of Cancer QLQ-BM22 was used for clinical assessment additionally to Visual Analog Scale (VAS), at baseline and 1, 3 and 6 months after treatment. All patients underwent CT and MRI before treatment and 3-6 months afterward.

Results and conclusions
Results: No treatment-related adverse events were recorded. 34/72 (47.2%) patients reported complete response to treatment and discontinued medications. 29/72 (40.3%) experienced a pain score reduction >2 points, consistent with partial response. Remaining 9 (12.5%) patients had recurrence after treatment. Statistically significant differences between baseline (6, 95%CI 5-8) and follow-up (2, 95%CI 0-3) VAS values and medication intake were observed (p<0.05). Similarly a significant difference was found for QLQ-BM22 between baseline and follow-up (p<0.05).

Conclusion: MRgFUS can be safely and effectively used as totally noninvasive treatment for pain palliation of bone metastasis in patients who had exhausted EBRT and also in patients not previously treated with EBRT.

Authors’ details
1University of Rome – Sapienza, Rome, Italy. 2The “Rizzoli” Orthopaedic Institute, Bologna, Italy.

Published: 30 June 2015

doi:10.1186/2050-5736-3-S1-O51

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

© 2015 Zaccagna et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.